GB2068969A - Gene expression - Google Patents

Gene expression Download PDF

Info

Publication number
GB2068969A
GB2068969A GB8100462A GB8100462A GB2068969A GB 2068969 A GB2068969 A GB 2068969A GB 8100462 A GB8100462 A GB 8100462A GB 8100462 A GB8100462 A GB 8100462A GB 2068969 A GB2068969 A GB 2068969A
Authority
GB
United Kingdom
Prior art keywords
process according
gene
plasmid
vehicle
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8100462A
Other versions
GB2068969B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GB2068969A publication Critical patent/GB2068969A/en
Application granted granted Critical
Publication of GB2068969B publication Critical patent/GB2068969B/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/77Ovalbumin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

A process for the expression of a gene, foreign to a host organism, coding for a protein, in a suitable vehicle, which comprises taking said gene and fusing it in the correct orientation relative to a transcriptional initiation region present in the vehicle, and inserting the vehicle into a eukaryotic host. For example, the gene for chicken ovalbumin can be expressed in the yeast Saccharomyces cerevisiae.

Description

SPECIFICATION Gene expression Many benefits in the medical field are envisaged as a result of the application of recombinant DNA technology. This technology requires the insertion, into host organisms, of genes able to direct the biosynthesis of required proteins. In most cases, a protein of interest will normally be synthesised in animal cells and will not be found naturally in yeast or other lower eukaryotes. Although it has been possible to clone a number of different animal genes containing the information necessary to code for proteins, there are few reports of the expression of these proteins in bacteria and other unicellular organisms. Some which have been expressed in E. coli are the human polypeptide hormone somatostatin (Itakura eft at Science 198 (1977) 1056--1063), rat proinsulin, and human insulin chains.
The chicken ovalbumin gene has been successfully expressed in E. coli Hub101, by fusing the gene near transcriptional and translational initiation regions. See Proceedings of National Academy of Sciences 6 (1978) 5936-5940. We have now found that the chicken ovalbumin structural gene can be fused to, for example, a S. cerevisiae transcriptional control region.
According to the present invention, a process for the expression of a gene in a vehicle, the gene coding for an animal or plant protein, comprises fusing the gene in the correct orientation relative to a transcriptional initiation region present in the vehicle, and inserting the vehicle into a eukaryotic host.
By way of example, when a plasmid containing the chicken ovalbumin structural hybrid gene is introduced into S. cerevisiae, a protein identified as ovalbumin by immunoreactivity and polyacrylamide gel electrophoresis can be synthesised. The chicken ovalbumin made in yeast is full-length (43,000 MW) and constitutes approximately 1,500 molecules per cell. We believe that this is the first animal protein expressed in yeast.
Examples of other proteins which can be produced using a gene inserted by the process of the present invention are human serum albumin, human interferons, human antibodies, human insulin, blood clotting factors, brain peptides, enzymes, viral antigens, and proteins from plants.
The gene may be derived from a plant or animal virus. Broadly, the invention relates to the expression of gene coding for proteins which are foreign to the host organism.
Preferabiy, the gene codes for an animal protein. The gene is suitably isolated from a vertebrate which is preferably warm-blooded, more preferably a bird and most preferably a chicken. The invention is particularly suited to the expression of genes coding for chicken ovalbumin.
A structural gene coding for a eukaryotic protein can generally be prepared using its purified messenger RNA (mRNA) as starting material. A complementary DNA (cDNA) copy of the mRNA is enzymatically synthesised and then enzymatically made double-stranded. This gene is then joined to a suitable cloning vehicle, usually by the poly dA; poly dT tailing procedure (Jackson eft at Proc.
Nat. Acad. Sci. (69 (1972) 2904-2909), although this is not always necessary. The vehicle containing the structural gene is then amplified in bacteria. This procedure has been used to prepare the pOV 230 plasmid, as well as plasmids containing globin genes and insulin genes.
Examples of other vehicles which can be used in the invention are any that can replicate within yeast, such as a plasmid, e.g. YEp2, YEp4, YRp7, YEp20 or, preferably, YEp6. Vectors which can replicate in other lower eukaryotic hosts can be used.
Examples of hosts for the vehicle are S. cerevisiae and derivatives thereof. The host is preferably a unicellular organism such as a fungus.
It is recognised that these latter hosts would have to be approved, at least in the USA, by the NIH Guidelines.
The plasmids (YEp6, pOV 230 and pUC 1014) described herein have been deposited in E. coli hosts in the permanent collection of the Northern Regional Research Laboratory, US Department of Agriculture, Peoria, Illinois, USA. Their accession numbers in this repository are HB101-NRRL B 11371;HBl0l (pOV230)-NRRLB-11354; HB101 (YEp 6)-NRRL B-12093; and HB101 (pUC 101 4)-NRRL B-12094. These NRRL deposits were made on 26th July 1 978 (B 11354),9th August 1978 (B-11371) and 31 st January 1980 (B-12093 and B-12094).
pUC 1014 has also been deposited in S. cerevisiae SHY 3 strain which is an NIH approved HV 2 host. The accession numbers of these yeast deposits are: S cerevisiae SHY 3 strain-NRRL Y-1 2095 and CBS (Holland) 8026; SHY 3 (pUC 1014)-NRRLY-12096 and CBS 8025. These two NRRL deposits were made on 31st January 1980.
The YEp6 plasmid (Struhl etna!., Proc. Nat.
Acad. Sci. 76(1979)1035-1039) contains an E. coli replication origin and ampicillin resistance marker derived from pBR322 so that it can be maintained in E. coli. In addition it contains a yeast plasmid replication origin and yeast His3 gene so that it can be maintained in his- yeast auxothrophs. The YEp6 plasmid also has a unique Sal I restriction endonuclease site which can be used for cloning foreign DNA.
Construction of the YEp6-ovalbumin fused plasmid, pUC 1014, proceeds as shown in the accompanying drawing. Although the abbreviations used here and throughout are conventional and well known to those skilled in the art, they are redefined here to facilitate a clear understanding of the invention: Restriction endonucleases: SAL I (in the Example).
Tc' -- tetracycline resistance gene.
ampr - ampicillin resistance gene.
Yeast his 3 gene - gene coding for an enzyme required for the biosynthesis of histidine in yeast.
T4 DNA ligase -- enzyme coded for by bacteriophage T4.
YEp - yeast episomal plasmid.
pUC - official designation for a plasmid owned by The Upjohn Company.
pOV - plasmid ovalbumin.
Ovalbumin gene -- chicken ovalbumin structural gene.
The YEp6 plasmid is cut with Sal I and the resulting linear molecule is treated, advantageously with alkaline phosphatase, to remove the 5' phosphate groups on the ends of the molecule.
The pOV 230 plasmid contains nearly all of the ovalbumin mRNA sequence, including all of the information required to code for the amino acid sequence of chicken ovalbumin [McReynolds, L. A., Catterall, J. F. and O'Malley, B. W. (1977) Gene 2: 217--231]. This plasmid is cut with Sal I, ligated with the alkaline phosphatase-treated, Sal I cut YEp6 and transformed into E. coli.
Transformants are selected on ampicillin plates and their plasmid DNA's analyzed.
There are two possible orientations of the ovalbumin gene relative to the YEp6 plasmid, and these can be distinguished by Bam H1 digestion of the DNA and agarose gel electrophoresis.
Preparations of the plasmid DNA's are made by growth in E. coli and used to transform S. cerevisiae. His+ transformations are selected on supplemented minimal media plates under conditions where the His parents can not grow.
The transformants are then grown in broth and lysed by passage through a French pressure cell.
The extracts are analyzed for ovalbumin immunoreactivity with an 1251 solid phase radioimmunoassay.
As determined by this immunoassay, only one of the two possible orientations of the ovalbumin gene relative to the YEp6 plasmid is capable of directing the synthesis of ovalbumin in yeast. The hybrid plasmid with this orientation, called pUC 1014, requires transcription of the ovalbumin gene in the counterclockwise direction of the plasmid illustrated in the drawing. The other orientation requires transcription in the clockwise direction. Thus, the ovalbumin gene is only expressed in yeast if it is fused into the YEp6 plasmid in the correct orientation relative to a yeast transcriptional initiation region.
Polyacrylamide gel electrophoresis of the chicken ovalbumin made in yeast indicates that it migrates with a mobility almost identical to that of ovalbumin synthesized in chicken oviduct. Some differences in mobility would be expected due to incomplete post-translational modifications of the ovalbumin made in yeast. Thus, the normal translational initiation site of the chicken gene is most probably used by the yeast translational machinery.
The following examples are illustrative of the process and products of the subject invention but are not to be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.
EXAMPLE 1 DNA Preparation pOV 230 Plasmid DNA from NRRL B-11354 is isolated by the salt precipitation technique described by Guerry eft at [Guerry, P., LeBlanc, D. J. and Falkow, S. (1973) J. Bact. 116: 1064-1066]. L-broth [Lennox, E.S. (1955) Virology 1: 190--206] containing 10 Mg/ml tetracycline is inoculated with an overnight broth culture of NRRL B-11354. Cultures are shaken vigorously at 370 C. until the optical density at 600 nm reaches 0.8; plasmid copy number is then amplified for 18 hours with chloramphenicol (250 g/ml). Cells are washed once in 50 mM Tris HCl, pH 8.0, 20 mM EDTA, and resuspended in 33 ml of 25% sucrose in TE (10 mM Tris HCI, pH 8.0,0.1 mM EDTA) per liter of culture.
Following the addition of 1 mg/ml lysozyme, the suspension is incubated on ice for five minutes, followed by addition of 1/3 volume of 0.25 M EDTA, pH 8.0 and another 5 minute incubation on ice. Cells are lysed by addition of 10% sodium dodecyl sulfate (SDS) in 37 mM Tris HCI, pH 8.0, 67 mM EDTA, to a final concentration of 1.3% followed by incubation at 370 C. for 30 minutes.
Chromosomal DNA is salted out by bringing the NaCI concentration to 1 M; followed by cooling at 40 C. overnight. SDS and chromosomal DNA are removed by centrifuging at 17,000 x g for 30 minutes at 40 C. The resulting supernatant is ethanol precipitated, pelleted, and redissolved in TE. This material is phenol extracted twice, ether extracted, ethanol precipitated, pelleted and resuspended in TE.
Plasmid DNA is further purified by cesium chloride-ethidium bromide density gradient centrifugation. Cesium chloride is dissolved in the DNA solution at a ratio of 1:1 (wt. vol.), followed by addition of 550 Lg/ml ethidium bromide.
Gradients are centrifuged for approximately 40 hours at ca. 100,000 x g. Plasmid DNA is removed from the gradient by needle puncture, and the ethidium bromide extracted with H20saturated 1-butanol. DNA is then dialyzed in 10 mM Tris HCI, pH 8.0,0.1 mM EDTA, followed by a final ethanol precipitation. Purified plasmid DNA is dissolved in 10 mM Tris HCI, pH 8.0, 0.1 mM EDTA.
If ampicillin is substituted for tetracycline in the method described above for preparing pOV 230 DNA, the method can also be used to prepare YEp6 DNA and pUC 1014 DNA in E. coli. Other plasmid DNA's can be prepared by this method if an appropriate selection (i.e., another antibiotic) is used to maintain the plasmid in the culture. Also, it is within the skill of those in the art to vary the above conditions to prepare plasmid DNA.
EXAMPLE 2 Restriction Endonuclease Digestions Sal I digestion of YEp6 DNA and pOV 230 DNA, prepared as described in Example 1, is done in a reaction mixture containing 6 mM Tris HCI, pH 8.0,6 mM MgCI2, 150 mM NaCI, 6 mM ,B- mercaptoethanol, 100 Mgm/ml autoclaved gelatin, 80 ygm/ml DNA and 80 units/ml Sal I restriction endonuclease. After incubation for 60 minutes at 370 C., the reaction mixture is phenol extracted, ether extracted and ethanol precipitated. It should be realized that the use of another vehicle might require the use of a different restriction endonuclease.
It is within the skill of those in the art to vary the concentrations of reagents, substrates and enzymes as well as reaction conditions to obtain the desired cleavages.
EXAMPLE 3 Alkaline Phosphatase Treatment This procedure is carried out essentially as described by Ullrich et al. [Ullrich, A., Shine, J., Chirgwin, J., Pictet, R., Tischer, E., Rutter, W. J.
and Goodman, H. M. (1977) Science 196: 131 3-i 31 9] with some minor modifications.
Twelve Units/ml of bacterial alkaline phosphatase (BAPF, Worthington) in 20 mM Tris HCI, pH 8.0, are pre-incubated at 700 C. for 10 minutes. One hundred Mgm/ml of Sal I cut YEp6 DNA, prepared as described in Example 2, is then added and incubation at 700 C. continues for 1 5 minutes.
The reaction mixture is then phenol extracted three times, ether extracted, and ethanol precipitated. This procedure is optional in the preparation of pUC 1014. However, use of the procedure affords a higher ratio of pUC 1014 to parental YEp6 plasmid among ampicillin resistant transformants, thereby facilitating the recovery of pUC 1014.
EXAMPLE4 T4 DNA Ligase In order to ligate the pOV 230 DNA to the alkaline phosphatase treated YEp6 DNA, prepared as described in Example 3, the reaction mixture contains 50 mM Tris HCI, pH 7.8, 10 mM MgCI2, 20 mM dithiothreitol, 1 mM ATP, 30 ygm/ml YEp6 DNA, 6 Mg/ml Sal I cut pOV 230 and 15 Units/ml of T4 DNA ligase. After incubation for 1 6 hours at 12.50 C., the reaction mixture is ethanol precipitated and the pellet dissolved in TCM (10 mM Tris HCI, pH 8.0, 10 mM CaCI2, 10 mM MgCI2). It is within the skill of those in the art to vary the concentrations of reagents, substrates and enzymes, as well as reaction conditions, to obtain the desired ligations.
EXAMPLE 5 Transformation of E. coli One hundred twenty ml. of L-broth (1% tryptone, 0.5% yeast extract, 0.5% NaCI) are inoculated with an 18 hour culture of Hub 101 NRRL B-11371 and grown to an optical density of 0.6 at 600 nm. Cells are washed in cold 10 mM MgSO4 and resuspended for 15 minutes in 20 ml chilled 50 mM CaCI2. Bacteria are then concentrated to one-tenth of this volume in CaCI2 and mixed 2 :1 (v :v) with ligated DNA, prepared as described in Example 4. After chilling the cell-DNA mixture for 1 5 minutes, it is heat shocked at 420 C. for 2 minutes, then allowed to equilibrate at room temperature for ten minutes before addition of L-broth 2-1/3 times the volume of the cell-DNA suspension.Transformed cells are incubated in broth at 370 C. for one hour before inoculating selective media (L-agar plus 20 4g/ml ampicillin) with 200 ,aVper plate. Plates are incubated at 370C, for 48 hours to allow the growth of transformants. Although the transformation procedure is essential for the amplification of biochemically constructed recombinant DNA molecules, the choice of conditions for such a procedure can be changed by those skilled in the art to achieve the desired purpose.
EXAMPLE 6 Transformation of NRRL Y-12095 to NRRL Y12096 SHY 3 strain of Saccharomyces cerevisiae (uratrp-leu-his-ade-), NRRL Y-i 2095 is transformed as follows: Twenty ml of log phase culture grown in YEPD broth (1% yeast extract, 2% peptone, 2% glucose) to an OD600 of 2.0 (3 x 107 cells/ml) were pelleted and resuspended in 1/10 volume 0.9 M sorbitol, 50 mM KPO4 buffer, pH 7.5, 14 mM p-mercaptoethanol. Spheroplasts are formed by addition of 1% Glusulase (Endo Laboratories) and incubation at 300 C. for 60 minutes.After washing three times in 1 M sorbitol, spheroplasts are resuspended in 1/100 original culture volume of 1 M sorbitol, 10 mM Tris-HCI, pH 7.5, 10 mM CaCI2. pUC 1014 DNA is added to a final concentration of 20,ug/ml. After incubation at room temperature for 5 minutes, 10 volumes of 40% polyethylene glycol 4000, 10 mM tris-HCI, pH 7.5, 10 mM CaC12 are added, followed by 10 minutes incubation at room temperature.His+ transformations are selected by overlaying minimal agar [0.7% yeast nitrogen base (Difco), 2% glucose,2% agarose, supplemented with 20 yg/ml uracil, adenine and tryptophan and 30 Mg/ml leucine] with 0.2 ml cells suspended in 10 ml molten (450 C.) regeneration medium (minimal medium containing 1 M sorbital, 2% YEPD and 3% agarose). Plates are incubated at 280 C. for 5-6 days.
EXAMPLE 7 Yeast Cell Extract Preparation Yeast cells grown in 100 ml minimal medium at 280 C. to early stationary phase are washed in Dulbecco's phosphate buffered saline (Gibso) and resuspended in extraction buffer (1 mM Tris-HCI pH 7.4, 1 mM MgCl2, 5 mM NaCI) at a ratio of 1:1 (volume in ml: cell weight in gm). The slurry is put through a French pressure cell twice at 15,000 PSI to lyse the cells.
EXAMPLE 8 Solid Phase Radioimmunoassay This is done by a slight modification of the method described by Broome and Gilbert [Proc.
Nat. Acad. Sci., 75: 2746-2749, 1978].
Polyvinyl chloride sheets (8 mils thick, made by Dora May Co., obtained at Woolworth's) 8 cm in diameter, are floated for 2 minutes at room temperature on 10 ml. of .2 M NaHCO3 (pH 9.2) containing 600 ssgm of the IgG fraction from antiovalbumin goat serum. The polyvinyl is then turned over and the other side coated. The polyvinyl is then washed with a solution (wash buffer) containing phosphate-buffered saline, 0.5% normal rabbit serum and 0.1% bovine serum albumin. After washing, the sheets are placed in contact with protein to be tested for the presence of immunoreactive ovalbumin. If cell lysates are to be tested, it is most convenient to spot the lysate on an agarose gel matrix. Proteins within a polyacrylamide gel matrix can also be tested after they had been separated by electrophoresis.The IgG-coated polyvinyl is placed in contact with either the agarose or polyacrylamide gel matrixes, and incubated in the refrigerator (approximately 40 C.) for several hours. The polyvinyl sheet is then placed in contact with [1251] labelled antiovalbumin IgG and incubated overnight in the refrigerator. After rinsing in wash buffer, the sheets are autoradiographed with Kodak XR-5 film and a duPont Cronex Hi- plus intensifying screen at 700 C.
EXAMPLE 9 Purification of Ovalbumin The transformed yeast cells of Example 6 are grown in minimal medium (0.7% yeast nitrogen base, 2% glucose supplemented with 20 mg/ml uracil, adenine and tryptophan, and 30 ssg/ml leucine) to early stationary phase, and washed in Dulbecco's phosphate buffered saline (Gibco). The cells, contained ovalbumin, are then resuspended in extraction buffer (1 mM Tris-HCI, pH 7.4, 1 mM MgCl2, 5 mM NaCI) at a ratio of 1:1 (volume in ml: cell weight in gm). The slurry is put through a French pressure cell at 1 5,000 PSI to lyse the cells. Purification to obtain crystalline ovalbumin, for use in the baking industry or for research purposes, carl be carried out as described by Shepherd etna!. in Methods in Carbohydrate Research Vol. VII (1976) ed. Whistier, and BeMiller, Academic Press, New York, pages 1 72-1 74. Crystalline ovalbumin is listed in the sales catalogues of various fine chemical suppliers.
The plasmic pUC 1014 and the yeast culture SHY 3 (pUC 1014) CBS 8025 form further aspects of the present invention. A further process of the present invention is for preparing chicken ovalbumin, a process comprising culturing S. cerevisiae SHY 3 (pUC 1014) CBS 8025 in an aqueous nutrient medium. The conditions will normally be controlled as necessary.

Claims (20)

1. A process for the expression of a gene coding for an animal or plant protein in a vehicle, which comprises fusing the gene in the correct orientation relative to a transcriptional initiation region present in the vehicle, and inserting the vehicle into a eukaryotic host.
2. A process according to claim 1 wherein the gene codes for a plant protein.
3. A process according to claim 1 wherein the gene is from a plant virus.
4. A process according to claim 1 wherein the gene codes for an animal protein.
5. A process according to claim 1 wherein the gene is from an animal virus.
6. A process according to claim 4 wherein the gene is isolated from a vertebrate.
7. A process according to claim 6 wherein the vertebrate is warm-blooded.
8. A process according to claim 7 wherein the warm-blooded vertebrate is a bird.
9. A process according to claim 8 wherein the bird is a chicken.
10. A process according to claim 9 wherein the gene is the chicken ovalbumin structural gene.
11. A process according to any preceding claim wherein the vehicle is a plasmid.
12. A process according to claim 11 wherein the plasmid is YEp 6.
13. A process according to any preceding claim wherein the host is foreign to the gene.
14. A process according to any preceding claim wherein the host is a unicellular organism.
1 5. A process according to claim 14 wherein the transcriptional initiation region naturally initiates mRNA synthesis in the unicellular organism.
1 6. A process according to claim 1 substantially as exemplified herein.
1 7. A process according to claim 14 or claim 1 5 wherein the unicellular organism is a fungus.
1 8. A process for preparing chicken ovalbumin, which comprises culturing S. cerevisiae SHY 3 (pUC 1014), CBS 8025, in an aqueous nutrient medium.
19. SHY 3 (pUC 1014) CBS 8025.
20. Plasmid pUC 1014.
GB8100462A 1980-02-05 1981-01-08 Gene expression Expired GB2068969B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11903780A 1980-02-05 1980-02-05

Publications (2)

Publication Number Publication Date
GB2068969A true GB2068969A (en) 1981-08-19
GB2068969B GB2068969B (en) 1983-07-27

Family

ID=22382245

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8100462A Expired GB2068969B (en) 1980-02-05 1981-01-08 Gene expression

Country Status (5)

Country Link
JP (1) JPS56109588A (en)
DE (1) DE3102036A1 (en)
FR (1) FR2476126B1 (en)
GB (1) GB2068969B (en)
IT (1) IT8119504A0 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068646A1 (en) * 1981-06-08 1983-01-05 The Upjohn Company Process for expressing the bovine growth hormone gene, and plasmid for use therein
EP0073635A2 (en) * 1981-08-25 1983-03-09 Celltech Limited Expression vectors
EP0088632A2 (en) * 1982-03-08 1983-09-14 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
WO1984001173A1 (en) * 1982-09-15 1984-03-29 Immuno Nuclear Corp Production of mature proteins in transformed yeast
US4472502A (en) * 1982-08-16 1984-09-18 The Regents Of The University Of California Malolactic gene
EP0183070A2 (en) * 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
US5045463A (en) * 1983-12-20 1991-09-03 Cetus Corporation DNA expression vector and use thereof
US5096825A (en) * 1983-01-12 1992-03-17 Chiron Corporation Gene for human epidermal growth factor and synthesis and expression thereof
WO1994028126A2 (en) * 1993-05-20 1994-12-08 University Of Warwick Phenylalanine-free protein and dna coding therefor
GB2294464A (en) * 1993-05-20 1996-05-01 University Of Warwick Phanylalanine-free protien and dna coding therefor
US5854018A (en) * 1981-02-25 1998-12-29 Washington Research Foundation Expression of polypeptides in yeast

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58192900A (en) * 1982-05-04 1983-11-10 Ajinomoto Co Inc Complex plasmid
JPH0616713B2 (en) * 1982-06-10 1994-03-09 味の素株式会社 Complex plasmid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2458585A1 (en) * 1979-06-07 1981-01-02 Pasteur Institut Genetically engineered proteins for nutrition - prepd. from ovalbumin

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856123A (en) * 1981-02-25 1999-01-05 Washington Research Foundation Expression of polypeptides in yeast
US5919651A (en) * 1981-02-25 1999-07-06 Washington Research Foundation Expression of polypeptides in yeast
US5854018A (en) * 1981-02-25 1998-12-29 Washington Research Foundation Expression of polypeptides in yeast
EP0068646A1 (en) * 1981-06-08 1983-01-05 The Upjohn Company Process for expressing the bovine growth hormone gene, and plasmid for use therein
EP0073635A3 (en) * 1981-08-25 1984-05-16 Alan John Kingsman Expression vectors
US4615974A (en) * 1981-08-25 1986-10-07 Celltech Limited Yeast expression vectors
EP0073635A2 (en) * 1981-08-25 1983-03-09 Celltech Limited Expression vectors
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
GB2116567A (en) * 1982-03-08 1983-09-28 Genentech Inc Expression processing and secretion of heterologous protein by yeast
FR2523152A1 (en) * 1982-03-08 1983-09-16 Genentech Inc PROTEIN PRODUCT FOR EXPRESSION AND TREATMENT BY A MICROORGANISM AND METHOD FOR PRODUCING THE SAME
EP0088632A3 (en) * 1982-03-08 1984-06-20 Genentech, Inc. Expression processing and secretion of heterologous protein by yeast
EP0088632A2 (en) * 1982-03-08 1983-09-14 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4472502A (en) * 1982-08-16 1984-09-18 The Regents Of The University Of California Malolactic gene
WO1984001173A1 (en) * 1982-09-15 1984-03-29 Immuno Nuclear Corp Production of mature proteins in transformed yeast
US5096825A (en) * 1983-01-12 1992-03-17 Chiron Corporation Gene for human epidermal growth factor and synthesis and expression thereof
US5045463A (en) * 1983-12-20 1991-09-03 Cetus Corporation DNA expression vector and use thereof
EP0183070A3 (en) * 1984-10-30 1987-09-30 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0183070A2 (en) * 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation of yeasts of the genus pichia
WO1994028126A2 (en) * 1993-05-20 1994-12-08 University Of Warwick Phenylalanine-free protein and dna coding therefor
WO1994028126A3 (en) * 1993-05-20 1995-01-26 Univ Warwick Phenylalanine-free protein and dna coding therefor
GB2294464A (en) * 1993-05-20 1996-05-01 University Of Warwick Phanylalanine-free protien and dna coding therefor
GB2294464B (en) * 1993-05-20 1998-03-11 Univ Warwick Phenylalanine-free protein and DNA coding therefor
US6495344B1 (en) 1993-05-20 2002-12-17 Pharming Holding N. V. Phenylalanine-free protein and DNA coding therefor

Also Published As

Publication number Publication date
FR2476126B1 (en) 1985-07-05
DE3102036A1 (en) 1981-12-03
JPS56109588A (en) 1981-08-31
GB2068969B (en) 1983-07-27
IT8119504A0 (en) 1981-02-04
FR2476126A1 (en) 1981-08-21

Similar Documents

Publication Publication Date Title
US4443539A (en) Process for preparing bovine growth hormone
KR890003083B1 (en) Method for preparation of tetracycline resistance gene having microorganism
US4440859A (en) Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
JP2552808B2 (en) Method for producing polypeptide
GB2068969A (en) Gene expression
US4430428A (en) Composition of matter and process
US4382028A (en) Separation of plasma proteins from cell culture systems
CA1340173C (en) Production and purification of a protein fused to a binding protein
US4652525A (en) Recombinant bacterial plasmids containing the coding sequences of insulin genes
JPH0665305B2 (en) Method for stabilizing host cell containing recombinant DNA
WO1984004535A1 (en) Heat regulated production of selected and fused proteins in yeast
Yeung et al. The purification of the Escherichia coli UvrABC incision system
GB2033905A (en) Bacterial preparation of proteins
US5082772A (en) Process for preparing deacetylcephalosporin c
US4649119A (en) Cloning systems for corynebacterium
JPS5998692A (en) Introduction of external gene in green algae by utilizing t-dna of agrobacterium
Pugsley et al. Increased production of the outer membrane receptors for colicins B, D and M by Escherichia coli under iron starvation
Vasantha et al. Isolation of a developmental gene of Bacillus subtilis and its expression in Escherichia coli.
JPS6156093A (en) Production of human white corpuscle interferon alpha-2
EP0163573B1 (en) Site-specific proteolysis by renin
EP0190119A1 (en) Chimeric plasmids that replicate in bacteria and yeast and microorganisms transformed therewith
CA2078365C (en) Pichia pastoris linear plasmids and dna fragments thereof
US5049501A (en) Production method for PvuI restriction endonuclease
EP0506262B1 (en) Production of L-fucose dehydrogenase
RU1660388C (en) Recombinant plasmid dna pvgib encoding bovine gamma-interferon, method of its preparing and yeast strain saccharomyces cerevisiae - a producer of bovine gamma-interferon

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee